Fong Clow
Corporate Officer/Principal chez SUMMIT THERAPEUTICS INC.
Profil
Fong Wang Clow is currently the Chief Biometrics Officer at Summit Therapeutics, Inc. Prior to this, Fong held positions as the VP-Biostatistics Programming & Data Management at Pharmacyclics LLC, Senior Vice President-Development at Novacea, Inc., and Head-Oncology Statistics at AbbVie, Inc. Fong completed their undergraduate degree at Wuhan University and holds graduate and doctorate degrees from Harvard T.H.
Chan School of Public Health.
Postes actifs de Fong Clow
| Sociétés | Poste | Début |
|---|---|---|
| SUMMIT THERAPEUTICS INC. | Corporate Officer/Principal | 16/10/2023 |
Anciens postes connus de Fong Clow
| Sociétés | Poste | Fin |
|---|---|---|
Novacea, Inc.
 Novacea, Inc. Pharmaceuticals: MajorHealth Technology Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea’s in-licensed product portfolio features three clinical stage oncology therapeutics. The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase 1/2 clinical trials. It is located in South San Francisco, CA. | Corporate Officer/Principal | 03/02/2009 |
| ABBVIE INC. | Corporate Officer/Principal | - |
| PHARMACYCLICS, INC. | Corporate Officer/Principal | - |
Formation de Fong Clow
| Wuhan University | Undergraduate Degree |
| Harvard T.H. Chan School of Public Health | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| SUMMIT THERAPEUTICS INC. | Health Technology |
| ABBVIE INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Novacea, Inc.
Novacea, Inc. Pharmaceuticals: MajorHealth Technology Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea’s in-licensed product portfolio features three clinical stage oncology therapeutics. The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase 1/2 clinical trials. It is located in South San Francisco, CA. | Health Technology |
Pharmacyclics LLC
 Pharmacyclics LLC Pharmaceuticals: MajorHealth Technology Pharmacyclics LLC engages in developing and commercializing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. It has product candidates in clinical development and several preclinical molecules in optimization. The company was founded by Jonathan Sessler and Richard Miller in 1991 and is headquartered in Sunnyvale, CA. | Health Technology |
